Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Even
about
Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery diseaseClinical use of new antithrombotic therapies for medical management of acute coronary syndromesCost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trialA randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END studyDosing and monitoring of low-molecular-weight heparins in special populations.Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy.New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins.Optimising outcomes: socioeconomic perspective.Regular review: treatment possibilities for unstable angina.Clinical trials of low-molecular-weight heparins in cardiology.Low-molecular-weight heparins for acute coronary syndromes: an emergency medicine perspective.Newer antithrombotic strategies in the initial management of non-ST-segment elevation acute coronary syndromes.Formulary management of low molecular weight heparins.Low molecular weight heparins and coronary artery disease.Low-molecular weight heparins in coronary artery disease.Therapy of unstable angina with the low molecular weight heparins.Low molecular weight heparins for arterial thrombosis.Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines.Cost effectiveness of treatments for non-ST-segment elevation acute coronary syndrome.The role of low-molecular-weight heparins in cardiovascular medicine.Low molecular weight heparin and atherosclerosis.Economics of unfractionated heparin: beyond acquisition cost.Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review.Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature.Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region.Cost effectiveness of anticoagulation in acute coronary syndromes.Unstable Angina.Heparin should be administered to every patient admitted to the hospital with possible unstable angina.Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis.Which heparin and how much?Pharmacotherapy of acute coronary syndromes: medical economics with an emphasis on clopidogrel.
P2860
Q24794056-DAB3DA34-378A-4A21-8F40-FFD900FD542AQ28177271-9FD1DC21-5D85-4827-A0FE-C216AB320393Q28194967-C90F7B7F-9DC9-4DCE-85DB-CEE1432FBC37Q28269998-5D7D2A57-04D7-4608-84EB-8749359DC728Q32049893-8E9004D7-5240-4EC6-821D-B9491B31B577Q33360869-40B589F9-D648-47E5-880F-691EA4E82464Q33576224-D2E6A0F9-374E-4FC3-9554-802C57A19773Q33723976-451C03B0-56DD-43C1-A528-0F35F2131D01Q33802938-ABD73602-189B-4F94-8C62-78514BCDAD0FQ33803411-D31D4724-AB79-4F8D-8C0C-701CF7D81A14Q33803415-7DEDBAEF-46C4-4D69-8012-2ECD7875C15FQ33838920-2E0F4037-5204-4C08-A000-0BCB77FF1784Q33881653-62DB3297-5247-4304-B0C7-77502801DA7DQ34027403-8D72EDD2-AC7D-4F62-9E53-71E837BF72DCQ34140745-F1B337DF-99A6-4824-99B8-5879EC5FB0DEQ34158934-B88EF256-E16A-4666-BDAE-2D7E8B5D3C10Q34158943-165D0CAF-AEAA-4973-8D62-7A9DF04B8304Q34445660-142F9A8F-8A0D-4E26-BC0D-7E85D8397C08Q35216895-7A004503-96EB-43A6-A4D5-3C526A29F8C8Q35591215-722BFF23-FAAC-440A-A2D7-668FC7227964Q35692023-234466E7-D927-427B-80F6-BFB6F312BBB5Q35873532-D5538BAC-95C1-4F8B-8DE1-BB50AF40F756Q36322605-AB2B51CF-C55B-4A4A-AE8C-1FB07217C069Q36545687-A23A94C4-540E-4AC1-A963-7FAFE38EEB71Q37627235-E7725400-9E6D-498C-BABC-E3C9DD26A58EQ37992680-135EAF63-92B7-42EF-A906-3D2936C0D476Q40737172-68A51534-E947-45E1-B89B-6FEFE8B46796Q42711606-87653C51-6F8B-40A3-B185-DB1F37768AEBQ45918884-3DE9457A-291B-455F-BE2C-53081EE158A0Q46494898-A4CFEB25-AA9E-4A2A-BD5F-D3BE9CBB073EQ46722941-3512797B-3871-478A-AB81-0BA4394D42EB
P2860
Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Even
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Economic assessment of low-mol ...... in in Non-Q wave Coronary Even
@en
Economic assessment of low-molecular-weight heparin
@nl
type
label
Economic assessment of low-mol ...... in in Non-Q wave Coronary Even
@en
Economic assessment of low-molecular-weight heparin
@nl
prefLabel
Economic assessment of low-mol ...... in in Non-Q wave Coronary Even
@en
Economic assessment of low-molecular-weight heparin
@nl
P2093
P1433
P1476
Economic assessment of low-mol ...... in in Non-Q wave Coronary Even
@en
P2093
Berkowitz SD
Davidson-Ray L
Weatherley B
P304
P356
10.1161/01.CIR.97.17.1702
P407
P577
1998-05-01T00:00:00Z